Predictive Oncology Inc.
POAI
$5.89
$0.346.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 33.33% | -97.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.33% | -97.55% | |||
| Cost of Revenue | -53.85% | -59.65% | |||
| Gross Profit | 69.68% | -123.77% | |||
| SG&A Expenses | 23.86% | 12.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.32% | 11.06% | |||
| Operating Income | -23.31% | -16.31% | |||
| Income Before Tax | -3,823.73% | 13.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3,823.73% | 13.41% | |||
| Earnings from Discontinued Operations | 94.43% | 41.84% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3,650.39% | 15.24% | |||
| EBIT | -23.31% | -16.31% | |||
| EBITDA | -23.60% | -16.54% | |||
| EPS Basic | -3,045.75% | 33.45% | |||
| Normalized Basic EPS | -3,191.08% | 32.01% | |||
| EPS Diluted | -3,008.10% | 32.74% | |||
| Normalized Diluted EPS | -3,191.08% | 32.01% | |||
| Average Basic Shares Outstanding | 19.22% | 27.37% | |||
| Average Diluted Shares Outstanding | 19.22% | 27.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||